Research programme: nanotechnology-based therapeutics - Cerulean Pharma

Drug Profile

Research programme: nanotechnology-based therapeutics - Cerulean Pharma

Alternative Names: cabazitaxel NDCs; cabazitaxel β-cyclodextrin-PEG copolymer-based nano-particle-drug conjugate; CRLX 288

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerulean Pharma
  • Class Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top